CRIS Current Research Information System

LANDUZZI, LORENA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 4.518
AS - Asia 3.655
EU - Europa 3.243
AF - Africa 257
SA - Sud America 172
OC - Oceania 4
Continente sconosciuto - Info sul continente non disponibili 2
Totale 11.851
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 4.443
VN - Vietnam 1.052
CN - Cina 1.014
SG - Singapore 961
IT - Italia 856
GB - Regno Unito 631
DE - Germania 456
SE - Svezia 288
HK - Hong Kong 286
RU - Federazione Russa 161
IN - India 136
NL - Olanda 132
BR - Brasile 125
FR - Francia 123
CH - Svizzera 122
UA - Ucraina 116
IE - Irlanda 108
CI - Costa d'Avorio 105
TG - Togo 57
CA - Canada 56
KR - Corea 56
ZA - Sudafrica 55
FI - Finlandia 53
JP - Giappone 47
EE - Estonia 45
BG - Bulgaria 39
BE - Belgio 29
ID - Indonesia 28
JO - Giordania 24
PL - Polonia 20
AR - Argentina 17
MX - Messico 14
RO - Romania 14
SC - Seychelles 14
AT - Austria 11
LT - Lituania 11
NG - Nigeria 11
EC - Ecuador 10
TR - Turchia 9
CL - Cile 7
EG - Egitto 7
IR - Iran 7
GR - Grecia 6
MA - Marocco 6
CO - Colombia 5
HR - Croazia 5
IQ - Iraq 5
PK - Pakistan 5
AE - Emirati Arabi Uniti 4
BD - Bangladesh 4
DK - Danimarca 4
ES - Italia 4
MD - Moldavia 4
AU - Australia 3
A2 - ???statistics.table.value.countryCode.A2??? 2
KG - Kirghizistan 2
PE - Perù 2
PY - Paraguay 2
TW - Taiwan 2
UZ - Uzbekistan 2
VE - Venezuela 2
YE - Yemen 2
AF - Afghanistan, Repubblica islamica di 1
AL - Albania 1
AM - Armenia 1
AZ - Azerbaigian 1
BO - Bolivia 1
BY - Bielorussia 1
DO - Repubblica Dominicana 1
DZ - Algeria 1
HN - Honduras 1
IL - Israele 1
JM - Giamaica 1
KH - Cambogia 1
LB - Libano 1
LI - Liechtenstein 1
LV - Lettonia 1
MK - Macedonia 1
MY - Malesia 1
NZ - Nuova Zelanda 1
PA - Panama 1
PS - Palestinian Territory 1
SA - Arabia Saudita 1
SN - Senegal 1
TT - Trinidad e Tobago 1
UY - Uruguay 1
Totale 11.851
Salva come PNG Salva come JPEG
Città #
Singapore 665
Southend 526
Fairfield 511
Ashburn 495
Chandler 481
Hong Kong 285
Ann Arbor 240
Woodbridge 237
Houston 219
Ho Chi Minh City 210
Seattle 208
Wilmington 206
Bologna 198
Dong Ket 198
Hanoi 183
Shanghai 177
Cambridge 166
Hefei 148
Santa Clara 144
Princeton 133
Beijing 114
Bern 112
Dublin 108
Abidjan 105
Boardman 101
Frankfurt am Main 87
Jacksonville 75
Dallas 59
Lomé 57
Nanjing 53
Seoul 53
Westminster 53
Bremen 52
Los Angeles 48
Milan 48
Padova 45
Tokyo 44
Berlin 43
Sofia 39
Guangzhou 35
Helsinki 35
Buffalo 31
Jinan 31
San Diego 31
Shenyang 30
Brussels 28
Saint Petersburg 26
Turin 26
Redondo Beach 25
Amman 24
Amsterdam 24
Des Moines 24
Falkenstein 24
Ottawa 24
Jakarta 23
Redmond 23
Redwood City 23
Casalecchio di Reno 22
London 22
Phoenix 21
Da Nang 20
Hebei 19
Nanchang 19
New York 19
Changsha 18
Hải Dương 17
Biên Hòa 16
Mülheim 16
Ha Long 15
Haiphong 15
Tianjin 15
Toronto 15
Warsaw 14
Bengaluru 13
Can Tho 13
Florence 13
Quận Bình Thạnh 13
Yubileyny 13
Jiaxing 12
Lappeenranta 12
São Paulo 12
Verona 12
Zhengzhou 12
Abeokuta 10
Bühl 10
Nuremberg 10
San Jose 10
Bắc Ninh 9
Dearborn 9
Mahé 9
Moscow 9
Parma 9
Bắc Giang 8
Catanzaro 8
Falls Church 8
Kuban 8
Montreal 8
Ningbo 8
Ninh Bình 8
San Giovanni in Persiceto 8
Totale 7.970
Salva come PNG Salva come JPEG
Nome #
IFN-γ and CD38 in Hyperprogressive Cancer Development 381
Vaccines against human HER2 prevent mammary carcinoma in mice transgenic for human HER-2. 353
ROCK2 deprivation leads to the inhibition of tumor growth and metastatic potential in osteosarcoma cells through the modulation of YAP activity 343
Early stability and late random tumor progression of a HER2-positive primary breast cancer patient-derived xenograft 305
Bone sarcoma patient-derived xenografts are faithful and stable preclinical models for molecular and therapeutic investigations 280
A multi-DNA preventive vaccine for p53/Neu driven cancer syndrome 242
Integrated molecular characterization of patient-derived models reveals therapeutic strategies for treating CIC-DUX4 sarcoma 226
Preclinical therapy of disseminated HER-2+ ovarian and breast carcinomas with a HER-2-retargeted oncolytic herpesvirus. 221
Cancer Vaccines Co-Targeting HER2/Neu and IGF1R 215
CD99 Acts as an Oncosuppressor in Osteosarcoma. 201
Apc10.1: an ApcMin/+ intestinal cell line with retention of heterozygosity. 198
CD99 contributes to the EWS::FLI1 transcriptome by specifically affecting FOXM1-targets involved in the G2/M cell cycle phase, thus influencing the Ewing sarcoma genetic landscape 196
Virus-like particle display of HER2 induces potent anti-cancer responses 194
Inhibition of human tumor growth in mice by an oncolytic herpes simplex virus designed to target solely HER-2-positive cells. 193
A Quinoline-Based DNA Methyltransferase Inhibitor as a Possible Adjuvant in Osteosarcoma Therapy 191
Tamoxifen combined to anti-HER-2/neu cell vaccine does not hamper cancer immunopreventive efficacy 187
Multiorgan Metastasis of Human HER-2+ Breast Cancer in Rag2−/−;Il2rg−/− Mice and Treatment with PI3K Inhibitor 187
Advances in preclinical therapeutics development using small animal imaging and molecular analyses: the gastrointestinal stromal tumors model. 185
Endothelin-3 production by human rhabdomyosarcoma: A possible new marker with a paracrine role. 184
Evolution of HER2-positive mammary carcinoma: HER2 loss reveals claudin-low traits in cancer progression 175
Biological indicators of prognosis in Ewing’s sarcoma: an emerging role for lectin galactoside-binding soluble 3 binding protein (LGALS3BP). 173
Circulating miR34a levels as a potential biomarker in the follow-up of Ewing sarcoma 172
ADK-VR2, a cell line derived from a treatment-naïve patient with SDC4-ROS1 fusion-positive primarily crizotinib-resistant NSCLC: a novel preclinical model for new drug development of ROS1- rearranged NSCLC 171
Bioprofiling TS/A Murine Mammary Cancer for a Functional Precision Experimental Model 171
Preclinical evaluation of KIT/PDGFRA and mTOR inhibitors in gastrointestinal stromal tumors using small animal FDG PET. 170
An aza-macrocycle containing maltolic side-arms (maltonis) as potential drug against human pediatric sarcomas. 167
HER-2/neu tolerant and non-tolerant mice for fine assessment of antimetastatic potency of dendritic cell-tumor cell hybrid vaccines 167
In silico modeling and in vivo efficacy of cancer preventive vaccinations 167
Antimetastatic activity of a preventive cancer vaccine. 167
Targeting CD99 compromises the oncogenic effects of the chimera EWS-FLI1 by inducing re-expression of zyxin and inhibition of Gli1 activity 166
Evaluation of metastatic burden and recovery of human metastatic cells from a mouse model 165
Immune targeting of autocrine IGF2 hampers rhabdomyosarcoma growth and metastasis 164
Experimental results and related clinical implications of PET detection of epidermal growth factor receptor (EGFr) in cancer 161
Immunoprevention and immunotherapy of mammary carcinoma 161
Human responses against HER-2-positive cancer cells in human immune system-engrafted mice. 161
Tumor suppressor genes promote rhabdomyosarcoma progression in p53 heterozygous, HER-2/neu transgenic mice. 159
Expression of a functional CCR7 chemokine receptor inhibits the post-intravasation steps of metastasis in malignant murine mammary cancer cells 155
Opposing control of rhabdomyosarcoma growth and differentiation by myogenin and interleukin 4. 154
Lamin A and the LINC complex act as potential tumor suppressors in Ewing Sarcoma 154
CRISPR/Cas9-mediated deletion of Interleukin-30 suppresses IGF1 and CXCL5 and boosts SOCS3 reducing prostate cancer growth and mortality 152
HER2 isoforms co-expression differently tunes mammary tumor phenotypes affecting onset, vasculature and therapeutic response 152
Prevention and Therapy of Metastatic HER-2+ Mammary Carcinoma with a Human Candidate HER-2 Virus-like Particle Vaccine 151
Metformin as an adjuvant drug against pediatric sarcomas: hypoxia limits therapeutic effects of the drug. 151
Evaluation of Modified PEG-Anilinoquinazoline Derivatives as Potential Agents for EGFR Imaging in Cancer by Small Animal PET. 150
OX40 triggering concomitant to IL12-engineered cell vaccine hampers the immunoprevention of HER2/neu-driven mammary carcinogenesis 150
High metastatic efficiency of human sarcoma cells in Rag2/gamma c double knockout mice provides a powerful test system for antimetastatic targeted therapy 149
Synovial Sarcoma Preclinical Modeling: Integrating Transgenic Mouse Models and Patient-Derived Models for Translational Research 148
Immunological prevention of a multigene cancer syndrome 147
Genetic prevention of lymphoma in p53 knockout mice allows the early development of p53-related sarcomas 145
Inhibition of prostate carcinogenesis by combined active immunoprophylaxis. 144
Lipid rafts, caveolae, and epidermal growth factor receptor family: friends or foes? 143
Characterization of a genetic mouse model of lung cancer: a promise to identify Non-Small Cell Lung Cancer therapeutic targets and biomarkers. 143
TRAF6 regulates proliferation and differentiation of skeletal myoblasts 142
Expression of connective tissue growth factor (CTGF/CCN2) in a mouse model of rhabdomyosarcomagenesis. 141
Immunoprevention of mammary carcinoma in HER-2/neu transgenic mice is IFN-gamma and B cell dependent 136
Inhibition of connective tissue growth factor (CTGF/CCN2) expression decreases the survival and myogenic differentiation of human rhabdomyosarcoma cells 135
APC10.1 cells as a model for assessing the efficacy of potential chemopreventive agents in the ApcMin mouse model in vivo. 134
NVE-BEZ235 as a new therapeutic option for sarcomas. 133
Innovative Breakthroughs for the Treatment of Advanced and Metastatic Synovial Sarcoma 130
Preclinical in vivo study of new insulin-like growth factor-I receptor-specific inhibitor in Ewing’s sarcoma. 130
Molecular and cellular biology of rhabdomyosarcoma 129
Immunoprevention of HER-2/neu transgenic mammary carcinoma through an interleukin 12 engineered allogeneic cell vaccine 128
Proteomic and PROTEOMEX profiling of mammary cancer progression in a HER-2/neu oncogene-driven animal model system 127
Vaccines and other immunological approaches for cancer immunoprevention 125
RIP2 regulates growth and differentiation of normal myoblasts and of rhabdomyosarcoma cells. 119
Patient Derived Xenografts for Genome-Driven Therapy of Osteosarcoma 115
HER Tyrosine Kinase Family and Rhabdomyosarcoma: Role in Onset and Targeted Therapy 112
Up-regulation of EphB and ephrin-B expression in rhabdomyosarcoma. 111
Expression of an IGF-I receptor dominant negative mutant induces apoptosis, inhibits tumorigenesis and enhances chemosensitivity in Ewing's sarcoma cells 107
Targeting glutathione-S transferase enzymes in musculoskeletal sarcomas: a promising therapeutic strategy. 106
IL-1 Family Members in Bone Sarcomas 76
Genomic profiling of a collection of patient-derived xenografts and cell lines identified ixabepilone as an active drug against chemo-resistant osteosarcoma 54
Functional stability, progression and evolution of targeted drug sensitivity of HER-2-positive breast cancer patient-derived xenografts 46
Totale 12.143
Salva come PNG Salva come JPEG
Categoria #
all - tutte 33.408
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 33.408
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021819 0 0 0 0 0 0 43 132 130 57 49 408
2021/20221.471 122 48 104 58 123 86 39 107 81 128 337 238
2022/20231.923 183 227 111 277 123 132 67 104 278 73 176 172
2023/2024630 28 80 28 47 38 63 36 221 17 32 13 27
2024/20251.926 135 246 154 114 282 115 132 88 20 156 98 386
2025/20262.612 762 439 345 327 489 210 40 0 0 0 0 0
Totale 12.143